Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. Academic Article uri icon



  • Glioblastoma (GBM) is the most common primary brain cancer in adults and is virtually incurable. Recent studies have shown that cytomegalovirus (CMV) is present in majority of GBMs. To evaluate whether the CMV antigens pp65 and IE1, which are expressed in GBMs, could be targeted by CMV-specific T cells, we measured the frequency of T cells targeting pp65 and IE1 in the peripheral blood of a cohort of 11 sequentially diagnosed CMV-seropositive GBM patients, and evaluated whether it was feasible to expand autologous CMV-specific T cells for future clinical studies. All 11 CMV-seropositive GBM patients had T cells specific for pp65 and IE1 in their peripheral blood assessed by IFN╬│ enzyme-linked immunospot assay. However, the precursor frequency of pp65-specific T cells was decreased in comparison with healthy donors (P=0.001). We successfully reactivated and expanded CMV-specific T cells from 6 out of 6 GBM patients using antigen-presenting cells transduced with an adenoviral vector encoding pp65 and IE1. CMV-specific T-cell lines contained CD4 as well as CD8 T cells, recognized pp65 and IE1 targets and killed CMV-infected autologous GBM cells. Infusion of such CMV-specific T-cell lines may extend the benefits of T-cell therapy to patients with CMV GBMs.

publication date

  • February 1, 2012



  • Antigens, Viral
  • Brain Neoplasms
  • Glioblastoma
  • Immunotherapy, Adoptive
  • T-Lymphocytes


PubMed Central ID

  • PMC3280423

Scopus Document Identifier

  • 84856845120

Digital Object Identifier (DOI)

  • 10.1097/CJI.0b013e318247642f

PubMed ID

  • 22306904

Additional Document Info


  • 35


  • 2